Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Medical Crossfire®: How are the Experts Applying the Latest Advances for Patients with Mantle Cell Lymphoma?

Release Date: August 31, 2021
Expiration Date: August 31, 2022

Activity Overview

The Medical Crossfire®, one of PER’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, four key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of mantle cell lymphoma (MCL) across lines of care. This lively discussion will help place new developments into clinical context to help you optimize care for patients with MCL.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and hematologists who treat or are interested in the treatment of MCL. Other allied healthcare professionals, including nurse practitioners, physician assistants and nurses involved in the treatment and management of patients with MCL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Examine diagnostic and prognostic strategies for optimized treatment planning in mantle cell lymphoma (MCL).
  • Review ongoing studies and trial data which address clinical practice gaps in MCL.
  • Apply individualized patient considerations into clinical scenarios incorporating novel and emerging therapies in MCL.
  • Create individualized plans to educate patients and manage adverse events associated with CAR T cell therapies and BTK inhibitors for MCL.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Gregory J. Riely, MD, PhD
Peter Martin, MD
Associate Professor of Medicine
Department of Medicine
Weill Cornell Medicine
New York, NY


Disclosures: Grant/Research Support: Karyopharm Therapeutics. Consultant: ADCT Therapeutics; AstraZeneca; Bayer AG; BeiGene; Bristol Meyers Squibb; Cellectar Biosciences, Inc.; Gilead Sciences, Inc.; Incyte Corporation; Janssen Pharmaceuticals; Karyopharm Therapeutics; Morphosys AG; Regeneron Pharmaceuticals; Teneobio, Inc.; and Verastem Oncology.


Ramaswamy Govindan, MD
Jonathon B. Cohen, Md MS
Associate Professor, Hematology and Medical Oncology
Co-Director, Lymphoma Program
Chair, Data Safety and Monitoring Committee
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant/Research Support: AstraZeneca; Biolnvent; Bristol Meyers Squibb/Celgene Corporation; Genentech, Inc.; HutchMed; L.A.M Pharmaceutical Corp.; Loxo Oncology, Inc./Lilly; Novartis; and Takeda Oncology. Consultant: Adaptive Biotechnologies; Adicet Bio; Aptitude Health; AstraZeneca; BeiGene; Cellectar Biosciences; Janssen Pharmaceuticals; Kite/Gilead Sciences, Inc.; and Loxo Oncology, Inc./Lilly.

Vamsidhar Velcheti, MD
Kami Maddocks, MD
Clinical Professor of Hematology
Lymphoma Program Director
The Ohio State University
The James Comprehensive Cancer Center
Columbus, Ohio


Disclosures: Grant/Research Support Bristol Meyers Squibb; Merck; Novartis; and Pharmacyclics, an AbbVie company. Consultant: ADC Therapeutics; Beigene; Celgene Corporation; Janssen Pharmaceuticals; Karyopharm Therapeutics; Kite; Morphosys AG; Pharmacyclics, an AbbVie company; and Seattle Genetics.

Vamsidhar Velcheti, MD
Elizabeth Budde, MD, PhD
Associate Professor
Department of Hematology & HCT
City of Hope National Medical Center
Duarte, CA


Disclosures: Grant/Research Support: AstraZeneca. Consultant: Kite/Gilead Sciences, Inc.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By